维普期刊资源整合服务平台（V6.5）

57篇 您的检索式：作者名="Ketas"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Reduced expres sion of proapoptotic gene Bax isassociated with poor response rates to combination chemothe rapy and shorter survival in women with metastatic breast adenocarcinoma显示文摘	Krajewski S Blomquist C Franssila Keta	1995	Cancer Res1995，55，19：	1
2	Radiosensitivity of human ovarian carcinoma and melanoma cells to :, - rays and protons 显示文摘	Keta O Todorovi: D Popovi: N	2014	Arch Med Sci2014，10，3：	1
3	Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CA2R5 monoclonal antibody PRO 140显示文摘	Trkola A Ketas TJ Nagashima KA	2001	J Virol2001，75，2：	1
4	Phase 1/11 trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma显示文摘	Leonard JP Coleman M Ketas JC	2003	J Clin Oncol2003，21，16：	1
5	Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection显示文摘	Veazey RS Klasse PJ Ketas TJ	2003	J Exp Med2003，198，10：	1
6	Epratuzumab,a humanized anti-CD22 antibody,in aggressive non-Hodgkin's lymphoma:phase Ⅰ/Ⅱ clinical trial results显示文摘	Leonard JP Coleman M Ketas JC	2004	Clin Cancer Res2004，10，16：	1
7	Phase Ⅰ/Ⅱtrial of epratuzumab(humanized anti-CD22 antibody)in indolent non-Hodgkin's lymphoma显示文摘	Leonard JP Coleman M Ketas JC	2003	J Clin Oncol2003，21，16：	1
8	Phase Ⅰ/Ⅱ trial of epratuzumab (humanized anti-CD22 antibody ) in indolent non- Hodgkin' s lymphoma 显示文摘	Leonard JP Coleman M Ketas JC	2003	J Clin Oncol2003，21，16：	1
9	Phase Ⅰ/Ⅱ trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma显示文摘	Leonard JP Coleman M Ketas JC	2003	J Clin Oncol2003，21，16：	1
10	Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma 显示文摘	LEONARD J P COLEMAN M KETAS J	2005	J Clin Oncol2005，23，22：	1
11	Epratuzumab, a human- ized anti-CD22 antibody, in aggressive non-Hodgkin' s lymphoma: Phase Ⅰ/Ⅱ clinical trial results 显示文摘	Leonard JP Coleman M Ketas JC	2004	Clin Cancer Res2004，10，16：	1
12	Perinatal lead and mercury exposure in Austria显示文摘	Gundaeker C FrohIieh S Crat-Robrmeister Keta	2010	Science of the To- tal Environment2010，408，23：	1
13	Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma显示文摘	Leonard JP Coleman M Ketas J		0，，22：	1
14	Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction显示文摘	Ndrepepa G Tiroch K Keta D	2010	Circ Cardiovasc Interv2010，3，1：	1
15	Practitioner and patient perceptions of orthodontic treatment:is the patient always right?显示文摘	Mc Keta N Rinchuse DJ Close JM	2012	J Esthet Restor Dent2012，24，1：	1
16	Hyperho- mocystinemia and risk of isehemic stroke among young Asian adults 显示文摘	Tan NC ven Keta Subramanian N Saw SM	2002	Stroke2002，33，8：	1
17	Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficieney virus infection or prevent simian - human immunodeficiency virus infection 显示文摘	VeazeylR S Klasse P J Ketas T J	2003	J Ecp Med2003，198，10：	1
18	Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction显示文摘	Ndrepepa G Tiroch K Keta D	2010	Circ Cardiovasc Interv2010，3，：	1
19	Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis 显示文摘	Muldoon MF Mackey RH Sutton - Tyrrell Keta	2007	Stroke2007，38，8：	1
20	Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells 显示文摘	Ketas T Frank I Klasse P	2003	J Virol2003，77，4：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示